Melanotan MT-1 vs MT-2: Structure, Evidence and Regulatory Status

Names can mislead. MT-1 and MT-2 sound like two versions of one product, and that is the first thing worth correcting. Both grew out of research on alpha-melanocyte-stimulating hormone, or alpha-MSH, but changing a peptide's structure changes how it interacts with receptors—and changes the questions a researcher can ask about it.

The useful comparison is not simply which produces more pigmentation. It is how the molecules differ, what their studies measured, and why the clinical history of one cannot be handed over to the other.

The short answer

• MT-1, usually associated with Melanotan I or afamelanotide, is a linear peptide of 13 amino acids. MT-2 is a smaller cyclic peptide of seven amino acids.
• Both belong to melanocortin research. Afamelanotide's clinical pigmentation mechanism centres on MC1R, while MT-2 has broader melanocortin activity. Predominant activity is not exclusive activity.
• Afamelanotide is the active substance in the medicine Scenesse. That does not turn a research vial labelled MT-1 into an approved medicine or establish a safety profile for MT-2.

The shared starting point in biology

A receptor is a protein that responds to a molecular signal. The melanocortin family contains several receptor subtypes with different biological roles. MC1R is particularly relevant to signalling that regulates eumelanin, the brown-black form of melanin.

That is why alpha-MSH analogues attracted interest: researchers could investigate pigmentation by changing its molecular signal. A shared receptor family, however, does not mean identical actions. Structure, receptor subtype, concentration and biological model all influence the result.

A linear peptide has an open backbone rather than the ring-containing architecture of a cyclic analogue. Ring formation constrains the shapes a peptide can adopt; it is not simply a way to make a smaller version of the same molecule. Neither chain length nor cyclisation alone establishes clinical potency or safety.

One naming trap deserves a warning: Melanotan I and II are not the MT1 and MT2 melatonin receptors. Melatonin belongs to a different signalling system. Similar abbreviations should not merge sleep research with melanocortin pharmacology.

MT-1: a linear analogue with a specific clinical history

Afamelanotide is a modified alpha-MSH analogue with 13 amino acids. The EMA product information describes predominant binding to MC1R. The EMA public assessment report provides additional regulatory context on its pharmacology, including activity involving other melanocortin receptors. Calling it absolutely MC1R-exclusive would oversimplify that evidence.

Its clinical development focused on erythropoietic protoporphyria, or EPP, a rare condition associated with painful light sensitivity. The randomized afamelanotide trials compared implants containing the active substance with placebo implants in patients with EPP. A central outcome was time spent in direct sunlight without pain; quality-of-life outcomes were also assessed.

This design matters. The investigators were not just asking whether skin became darker. They were asking whether people with a defined disease could tolerate more light exposure without pain. Randomization and a placebo comparator made the comparison more informative than an uncontrolled observation of pigmentation. Nevertheless, exposure behaviour and diary-based measurements remain part of the interpretation, and the findings belong to the studied population and implant formulation.

These were not trials of general cosmetic tanning. The EMA Scenesse overview describes an authorised implant for a specific EPP indication and treatment setting. That authorisation does not extend automatically to every material sold as MT-1 or afamelanotide.

MT-2: a cyclic structure and a broader question

Melanotan II is a cyclic heptapeptide: a seven-amino-acid analogue with a ring-containing structure rather than the longer linear architecture of afamelanotide. Its broader melanocortin activity makes pigmentation only one part of its experimental profile.

An early phase-I pilot in three healthy male volunteers evaluated subcutaneous MT-II and saline. Increased pigmentation was reported in two subjects; other observations included nausea, stretching and yawning, and spontaneous erections. Somnolence and fatigue were also reported. These observations come from Dorr and colleagues, 1996. They identify responses worth investigating, not a general cosmetic benefit or an established long-term safety profile.

Three participants cannot adequately characterize uncommon adverse events, delayed effects or variation across a broad population. Nor can a historical study predict the performance of an untested retail formulation. Observing several biological effects is consistent with a broader pharmacological profile; it does not establish that the molecule is more useful overall.

MT-1 and MT-2 side by side

Why “stronger” and “safer” are incomplete claims

Stronger at which endpoint, in which model, over what period? Receptor activation, measured pigmentation and pain-free sunlight exposure are different measurements. Percentages from unrelated studies cannot substitute for a direct comparison with aligned populations, formulations and outcomes.

Safety requires the same precision. Clinical monitoring and manufacturing controls surrounding an authorised implant are part of its evidence context; they cannot be assumed for a research material. Absence of a reported problem in a small study also does not show that an uncommon or delayed problem cannot occur.

Pigment changes need careful interpretation. Darkening of an existing skin lesion is an observation, not a diagnosis and not, by itself, proof that a substance causes melanoma. Neither blanket reassurance nor a causal claim based on an isolated report is justified. As regulatory safety context, the MHRA statement warns about potentially serious effects associated with Melanotan II injections and nasal sprays; it is not an efficacy study.

Frequently asked questions

Is MT-1 simply a milder MT-2?

No. They are structurally different analogues with different pharmacology and evidence histories. “Milder” compresses receptor activity, formulation and safety into an unsupported single label.

Does Scenesse approval cover MT-1 research vials?

No. Approval concerns the specific medicinal product and its conditions of use. A shared molecule name does not establish equivalent manufacturing, formulation, clinical performance or regulatory status.

Can pigmentation replace sun protection?

That conclusion does not follow from these studies. Findings within a defined EPP treatment programme are not grounds to increase UV exposure or abandon established protective measures.

Is combining MT-1 and MT-2 supported?

The sources discussed here establish neither a clinical advantage nor a safety profile for that combination. Related mechanisms do not demonstrate a beneficial combined intervention.

Keeping the evidence trails separate

MT-1 and MT-2 are related molecules, not interchangeable versions of a tanning product. A useful comparison preserves three distinctions: molecular structure, the outcome actually measured, and the formulation and population in which it was measured.

For another example of similar names concealing meaningful structural differences, see our GHK-Cu and AHK-Cu comparison. For interpreting analytical evidence about research material, see HPLC, mass spectrometry and peptide quality.

This article is educational. Crystal Peptides research materials are not presented here as medicines or products for human use.